electroCore, Inc. (ECOR)

Market Cap	76.65M +114.3%
Revenue (ttm)	34.90M +31.9%
Net Income	-15.38M
EPS	-1.78
Shares Out	8.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	221,967
Open	9.24
Previous Close	9.24
Day's Range	8.79 - 9.36
52-Week Range	4.16 - 9.68
Beta	0.68
Analysts	Strong Buy
Price Target	19.17 (+107.47%)
Earnings Date	May 6, 2026

About ECOR

electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jun 22, 2018
• Employees: 83
• Stock Exchange: NASDAQ
• Ticker Symbol: ECOR
• Website: https://www.electrocore.com

Financial Performance

In 2025, electroCore's revenue was $32.03 million, an increase of 27.20% compared to the previous year's $25.18 million. Losses were -$13.97 million, 17.5% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for ECOR stock is "Strong Buy." The 12-month stock price target is $19.17, which is an increase of 107.47% from the latest price.

Price Target

$19.17

(107.47% upside)

Analyst Consensus: Strong Buy